|Product Description||NDC||Lot #||Expiration Date|
|Vistide ® (cidofovir injection)||61958-0101-1||B120217A||May 2015|
There could be a major windfall for Fortune 500 companies.
Jim Cramer likes Harley and Enterprise Products Partners, but says stay away from Costamare and Achaogen.
Jim Cramer explains how bullish comments from one semiconductor equipment maker lifts shares throughout the sector.
If you buy right, time and value should do most of the heavy lifting for you.